Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Truist Securities Maintains Buy on iRhythm Technologies, Lowers Price Target to $153

Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $167 to $153.
byBenzinga Newsdesk
December 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $167 to $153.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

IBio Divesting CDMO Business and CGMP Biologics Manufacturing Facility, to Result in About 50% Annualized Cost Savings; Commenced Workforce Reduction of Approximately 60% of Current Company Staffing Levels

By Charles Gross
November 3, 8:09 AM
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company.

IBIO